Interaction onset is a process, not simply the maximum effect listed in a table.
What the supplied source reports
Twenty-four volunteers received intravenous midazolam microdosing while selected groups received voriconazole, rifampicin, efavirenz or placebo. Parent and metabolite sampling supported a population model of changing clearance. The selected agents showed different onset and duration patterns for inhibition, induction or activation.
Limits and uncertainty
Treatment arms were very small and used specific single-exposure conditions. The time course cannot be generalized unchanged to repeated clinical dosing or other interacting drugs. A microdose clearance marker does not directly measure sedation, respiratory response or functional impairment.
Implications for forensic review
For an interaction timeline, distinguish when an interacting drug was started from when its enzyme effect emerged. Record route, repeated exposure and stop time. This experiment supports time-resolved pharmacokinetic reasoning while leaving the clinical consequences of a particular therapeutic combination to separate evidence.
Source and related reading
Source reviewed: Quantification of the Time Course of CYP3A Inhibition Activation and Induction Using a Population Ph (PMC9652212). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Canadian Death Review Distinguished Detected Drugs From Drugs Judged Contributory.
Leave a Reply